Rezapour Aziz, Bagheri Faradonbeh Saeed, Alipour Vahid, Yusefvand Mani
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Medicine (Baltimore). 2018 Mar;97(10):e9958. doi: 10.1097/MD.0000000000009958.
Cardiomyopathies is a group of heart diseases that directly affects the heart muscle, and their causes is not just high blood pressure, congenital and pericardial diseases but ischemic cardiomyopathy disease are also caused by vascular disorders, and to confirm the diagnosis, angiography is required. There are several methods for treating and controlling ischemic cardiomyopathy in world health systems and especially in the Iran health system, which include medical treatment, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG).
This systematic review will includes observational and interventional studies in English and Persian languages and evaluates effectiveness of revascularization interventions and medical therapy in patients with ischemic cardiomyopathy. Animal studies will not be considered. In this systematic review, our sources of information will be electronic databases, trial registries, and different types of grey literature. An electronic search is performed through PubMed, Cochrane library, Scopus, Web of Science, EMBASE, Tufts Medical Center Cost-Effectiveness Analysis Registry, NHS Economic Evaluations Database. To integrate the results of studies with similar results, meta-analysis will be used, for which Comprehensive Meta-Analysis (CMA) software will be used. Results are provided using relative risk with a 95% confidence interval for information.
The results of this systematic review will be published in a peer-reviewed journal.
To our knowledge, this systematic review will be the first to evaluate existing research on the effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy. The review will benefit patients, healthcare providers, and policymakers.
心肌病是一组直接影响心肌的心脏病,其病因不仅包括高血压、先天性和心包疾病,缺血性心肌病也由血管疾病引起,而确诊需要进行血管造影。在世界卫生系统,尤其是伊朗卫生系统中,有几种治疗和控制缺血性心肌病的方法,包括药物治疗、经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)。
本系统评价将纳入英文和波斯文的观察性和干预性研究,评估缺血性心肌病患者血运重建干预措施和药物治疗的有效性。不考虑动物研究。在本系统评价中,我们的信息来源将是电子数据库、试验注册库和不同类型的灰色文献。通过PubMed、Cochrane图书馆、Scopus、科学网、EMBASE、塔夫茨医学中心成本效益分析注册库、英国国家医疗服务体系经济评价数据库进行电子检索。为整合具有相似结果的研究结果,将使用荟萃分析,为此将使用综合荟萃分析(CMA)软件。结果以相对风险及95%置信区间提供信息。
本系统评价的结果将发表在同行评审期刊上。
据我们所知,本系统评价将首次评估缺血性心肌病患者血运重建干预措施与药物治疗有效性的现有研究。该评价将使患者、医疗服务提供者和政策制定者受益。